MiMedx Group Inc (MDXG)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at MiMedx Group Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 4.10 $ — 20% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
7 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 16.1% passed
- More than 10% revenue growth is expected for the coming year 12.4% passed
- Share count grows by less than 3% a year 9.9% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 37.4% failed
- Gross margin at 40% or higher and without meaningful erosion 82.6% passed
- Goodwill from acquisitions does not grow faster than revenue 5.7% passed
- Net debt below twice EBITDA 144 m net cash passed
- Operating cash flow covers the profits of the last three years 9 m passed
- Return on capital at 15% or higher, or up versus two years ago 23.0% passed
- Insiders hold at least 10% or are net buyers 2.1% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 61.0% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 5
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.10 | -0.10 – -0.10 | 270 | -122.2% | 1 |
| 12/31/2027 | 0.24 | 0.17 – 0.31 | 303 | 340.0% | 2 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.05 | -86.20 | 93 | 7.00 | 8.00 | 19 | 19 |
| 2025: Q1 | 0.05 | -24.00 | 88 | 4.10 | 8.00 | 5 | 5 |
| 2025: Q2 | 0.06 | -45.60 | 99 | 13.10 | 9.80 | 14 | 14 |
| 2025: Q3 | 0.11 | 105.00 | 114 | 35.30 | 14.70 | 29 | 25 |
| 2025: Q4 | 0.10 | 103.30 | 118 | 27.10 | 12.90 | 25 | 25 |
| 2026: Q1 | -0.07 | -255.90 | 59 | -33.10 | -18.40 | 2 | 1 |
| 2026: Q2 | -0.10 | -266.70 | 64 | -34.70 | -23.00 | -10 | -10 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 245 | 1 | 12 | 0.11 | 24 | 133 | 193 |
| 2017 | 321 | 46 | 65 | 0.56 | 63 | 74 | 121 |
| 2018 | 359 | -4 | -30 | -0.27 | 36 | 50 | 123 |
| 2019 | 359 | -4 | -30 | -0.28 | 36 | 50 | 123 |
| 2020 | 248 | -45 | -49 | -0.46 | -39 | 91 | 202 |
| 2021 | 242 | -7 | -12 | -0.11 | -2 | 93 | 188 |
| 2022 | 268 | -15 | -30 | -0.27 | -18 | 75 | 171 |
| 2023 | 321 | 37 | 67 | 0.46 | 27 | 143 | 239 |
| 2024 | 349 | 59 | 42 | 0.28 | 66 | 193 | 264 |
| 2025 | 419 | 64 | 49 | 0.32 | 74 | 257 | 343 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
MiMedx Group, Inc. entwickelt und vertreibt Plazentagewebe-Allografts für verschiedene Bereiche des Gesundheitswesens.
| Employees | 808 |
|---|---|
| Headquarters | Marietta, GA |
| Address | 1775 West Oak Commons Court, NE, 30062 Marietta, United States |
| Phone | 770 651 9100 |
| Website | mimedx.com |
| IPO Date | 22. Aug 2007 |
| ISIN | US6024961012 |
| Stock Split | 3235:10000 on 04/02/2008 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Joseph H. Capper | CEO & Director | 1964 |
| Douglas C. Rice CPA | Chief Financial Officer | 1966 |
| William F. Hulse IV | General Counsel & Chief Administrative Officer | 1974 |
| Kimberly Maersk-Moller | Chief Commercial Officer | 1967 |
| John Harper Ph.D. | SVP of R&D & Medical Affairs and Chief Scientific Officer | – |
| Matthew M. Notarianni | Head of Investor Relations | – |
| Mark P. Graves | Senior VP & Chief Compliance Officer | 1966 |
| Hilary Dixon | Vice President of Investor Relations & Corporate Strategic Communications | – |
| Eric A. Smith | Senior VP of Marketing & International | 1972 |
| Tracy Chastain | Chief Human Resources Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.